全文获取类型
收费全文 | 281篇 |
免费 | 32篇 |
出版年
2024年 | 1篇 |
2023年 | 3篇 |
2022年 | 1篇 |
2021年 | 9篇 |
2020年 | 11篇 |
2019年 | 4篇 |
2018年 | 12篇 |
2017年 | 9篇 |
2016年 | 9篇 |
2015年 | 7篇 |
2014年 | 15篇 |
2013年 | 24篇 |
2012年 | 26篇 |
2011年 | 21篇 |
2010年 | 14篇 |
2009年 | 15篇 |
2008年 | 13篇 |
2007年 | 18篇 |
2006年 | 17篇 |
2005年 | 16篇 |
2004年 | 18篇 |
2003年 | 19篇 |
2002年 | 4篇 |
2000年 | 2篇 |
1999年 | 6篇 |
1998年 | 5篇 |
1997年 | 2篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1988年 | 1篇 |
1984年 | 2篇 |
1976年 | 1篇 |
1968年 | 1篇 |
1961年 | 1篇 |
1945年 | 1篇 |
1931年 | 2篇 |
排序方式: 共有313条查询结果,搜索用时 0 毫秒
311.
Jingxuan Quek Cheng Han Ng Ansel Shao Pin Tang Nicholas Chew Mark Chan Chin Meng Khoo Chen Poh Wei Yip Han Chin Phoebe Tay Grace Lim Darren Jun Hao Tan Wen Hui Lim Kai En Chan Margaret Teng Eunice Tan Nobuharu Tamaki Daniel Q. Huang Mohammad Shadab Siddiqui Mark D. Muthiah 《Endocrine practice》2022,28(7):667-672
ObjectiveThe recent introduction of the term metabolic associated fatty liver disease (MAFLD) sought to reclassify nonalcoholic fatty liver disease (NAFLD). MAFLD is thought to improve the encapsulation of metabolic dysregulation. However, recent evidence has found significant differences between MAFLD and NAFLD, and prevailing knowledge has largely arisen from studies on NAFLD. Hence, we conducted a meta-analysis and systematic review of the outcomes associated with MAFLD.MethodsMEDLINE and Embase databases were searched for articles relating to outcomes in MAFLD. Analysis was conducted in random effects with hazard ratios (HRs) to account for longitudinal risk assessment of mortality and systemic complications.ResultsA total of 554 articles were identified, of which 17 articles were included. MAFLD resulted in an increase in the overall mortality (HR, 1.24; confidence interval [CI], 1.13-1.34), cancer-related mortality (HR, 1.27; CI, 1.01-1.54), and cardiovascular disease mortality (HR, 1.28, 1.03-1.53; P = .04) compared with non-MAFLD. MAFLD also increases the risk of cardiovascular events (HR, 1.49; CI, 1.34-1.64; P < .01), stroke (HR, 1.55; CI, 1.37-1.73; P < .01), and chronic kidney disease (HR, 1.53; CI, 1.38-1.68). The presence of MAFLD was also associated with an increased risk of heart failure, obstructive sleep apnea, and malignancy.ConclusionMAFLD can significantly elevate the risk of systemic diseases and mortality. The care of MAFLD thus requires interdisciplinary collaboration, and future clinical trials conducted on MAFLD should aim to reduce the incidence of end-organ damage aside from improving liver histology. 相似文献
312.
Jiachen Chen Margaret F. Doyle Yuan Fang Jesse Mez Paul K. Crane Phoebe Scollard ADSP Data Harmonization Consortium Cognitive Harmonization Core Claudia L. Satizabal Michael L. Alosco Wei Qiao Qiu Joanne M. Murabito Kathryn L. Lunetta 《Aging cell》2023,22(10):e13955
Inflammatory protein biomarkers induced by immune responses have been associated with cognitive decline and the pathogenesis of Alzheimer's disease (AD). Here, we investigate associations between a panel of inflammatory biomarkers and cognitive function and incident dementia outcomes in the well-characterized Framingham Heart Study Offspring cohort. Participants aged ≥40 years and dementia-free at Exam 7 who had a stored plasma sample were selected for profiling using the OLINK proteomics inflammation panel. Cross-sectional associations of the biomarkers with cognitive domain scores (N = 708, 53% female, 22% apolipoprotein E (APOE) ε4 carriers, 15% APOE ε2 carriers, mean age 61) and incident all-cause and AD dementia during up to 20 years of follow-up were tested. APOE genotype-stratified analyses were performed to explore effect modification. Higher levels of 12 and 3 proteins were associated with worse executive function and language domain factor scores, respectively. Several proteins were associated with more than one cognitive domain, including IL10, LIF-R, TWEAK, CCL19, IL-17C, MCP-4, and TGF-alpha. Stratified analyses suggested differential effects between APOE ε2 and ε4 carriers: most ε4 carrier associations were with executive function and memory domains, whereas most ε2 associations were with the visuospatial domain. Higher levels of TNFB and CDCP1 were associated with higher risks of incident all-cause and AD dementia. Our study found that TWEAK concentration was associated both with cognitive function and risks for AD dementia. The association of these inflammatory biomarkers with cognitive function and incident dementia may contribute to the discovery of therapeutic interventions for the prevention and treatment of cognitive decline. 相似文献
313.